ATLAS News · Companies

Hims & Hers Health shares fall after Q3 report and softer sales guidance

Published November 10, 2026 · 6 sources

Hims & Hers Health fell in the afternoon session after its third-quarter report and next-quarter sales guidance that came in below expectations, outlets report.

What happened

Shares of telehealth company Hims & Hers Health (HIMS) fell 18.5% in the afternoon session after the company reported third-quarter 2026 results, according to TradingView. The company also gave sales guidance for the next quarter that was below expectations.

Yahoo Finance reports that revenue rose nearly 49%, but investors sold anyway, pointing to shrinking margins, a slip in subscribers and a bet on branded GLP-1 drugs. The outlet also notes that Novo Nordisk slid 2% while Eli Lilly held steady.

Yahoo Finance also summarizes the earnings call as centered on a marketing reset and margin pressure. Yahoo! Finance Canada separately raised the topic of Andrew Huberman joining the company's board, while Seeking Alpha published a piece arguing against nitpicking the quarterly results.

Context

Hims & Hers Health is a telehealth company, and its business has been tied to interest in GLP-1 weight-loss drugs.

Why it matters

The reaction shows how closely investors are watching growth, margins and subscriber trends for the company.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Hims & Hers HealthHIMS

−16.61%

Healthcare · NYSE

Live price

$19.89▼ -16.61%

live price · USD

Close on November 10: $19.13−16.61% vs. previous close ($22.94)
Fair value (ATLAS): $25.75Fair range: $5.83 to $42.25The price ($19.89) is 22.8% below that figure.
Chance of a rise in 1 month: 44%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $15.90 and $22.92; 9 in 10, between $11.50 and $31.69.

See the full ATLAS analysis of Hims & Hers Health →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

Why Hims & Hers Health (HIMS) shares are getting obliterated today · TradingView · November 10, 2026
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady · Yahoo Finance · November 10, 2026
Why Is Hims & Hers Health Stock Falling Today? - Hims & Hers Health (NYSE:HIMS) · Benzinga · November 10, 2026
Why Is Hims & Hers Health (HIMS) Bringing Andrew Huberman Onto Its Board? · Yahoo! Finance Canada · November 10, 2026
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure · Yahoo Finance · November 10, 2026
Hims & Hers Health: Don't Nitpick Quarterly Results · Seeking Alpha · November 10, 2026

Latest market news · Markets today on ATLAS · Hims & Hers Health

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer